- Home
- LGMK vs BJDX Comparison
LGMK vs BJDX Comparison
Compare LGMK & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- BJDX
- Stock Information
- Founded
- LGMK 2011
- BJDX 2015
- Country
- LGMK United States
- BJDX United States
- Employees
- LGMK N/A
- BJDX N/A
- Industry
- LGMK Industrial Specialties
- BJDX Medical Specialities
- Sector
- LGMK Health Care
- BJDX Health Care
- Exchange
- LGMK Nasdaq
- BJDX Nasdaq
- Market Cap
- LGMK 1.6M
- BJDX 1.8M
- IPO Year
- LGMK N/A
- BJDX 2021
- Fundamental
- Price
- LGMK $0.10
- BJDX $3.17
- Analyst Decision
- LGMK
- BJDX
- Analyst Count
- LGMK 0
- BJDX 0
- Target Price
- LGMK N/A
- BJDX N/A
- AVG Volume (30 Days)
- LGMK 59.1M
- BJDX 48.0M
- Earning Date
- LGMK 11-12-2024
- BJDX 11-07-2024
- Dividend Yield
- LGMK N/A
- BJDX N/A
- EPS Growth
- LGMK N/A
- BJDX N/A
- EPS
- LGMK N/A
- BJDX N/A
- Revenue
- LGMK $10,078,502.00
- BJDX N/A
- Revenue This Year
- LGMK N/A
- BJDX N/A
- Revenue Next Year
- LGMK N/A
- BJDX N/A
- P/E Ratio
- LGMK N/A
- BJDX N/A
- Revenue Growth
- LGMK 4.44
- BJDX N/A
- 52 Week Low
- LGMK $0.07
- BJDX $0.07
- 52 Week High
- LGMK $2.20
- BJDX $31.28
- Technical
- Relative Strength Index (RSI)
- LGMK 43.72
- BJDX 97.41
- Support Level
- LGMK $0.07
- BJDX $0.07
- Resistance Level
- LGMK $0.16
- BJDX $0.14
- Average True Range (ATR)
- LGMK 0.03
- BJDX 0.06
- MACD
- LGMK 0.00
- BJDX 0.23
- Stochastic Oscillator
- LGMK 10.34
- BJDX 100.00
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.